Can Regeneron’s Odronextamab Stand Out With Better Safety?

The challenge for Regeneron Pharmaceuticals, Inc.’s CD20xCD3-targeting bispecific antibody odronextamab is to stand out in an increasingly crowded class that already has multiple approved agents, which data presented at the American Society of Hematology annual meeting suggest it may be able to do with a favorable toxicity profile, especially in terms of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).